Easton Bio Pharmaceuticals 苑东生物
30 significant filings since 29 May 2026: 22 on equity incentive and 8 on buyback. The latest, on 8 Sep 2026: 苑东生物：关于回购注销2024年员工持股计划部分股份并减少注册资本暨通知债权人的公告.
自 29 May 2026 起有 30 份重大公告：equity incentive 22 份、buyback 8 份。最新一份（8 Sep 2026）：苑东生物：关于回购注销2024年员工持股计划部分股份并减少注册资本暨通知债权人的公告。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 1 broker | 1 broker |
| 7 days ago | 1 broker | 1 broker |
| 30 days ago | 2 brokers | 2 brokers |
| 60 days ago | 1.70 | 1.86 |
| 90 days ago | 1.70 | 1.86 |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
Consensus moved from 2.28 in Sep 2024 to 1.70 in Jul 2026 (-25.4%). 一致预期从 Sep 2024 的 2.28 变为 Jul 2026 的 1.70 (-25.4%)。 The shaded band runs from the lowest to the highest broker forecast.
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 0 ▼ 0 = 0 | ▲ 0 ▼ 0 = 0 |
| Last 90 days | ▲ 0 ▼ 1 = 0 | ▲ 0 ▼ 1 = 0 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 0.